Investor Presentation

**Supriya Lifescience Q3FY26 & 9MFY26 Update:** 1. **Business Performance:** Strong Q3: Revenue up 11% YoY to ₹206.44 Cr, PAT +6% to ₹49.68 Cr (EPS ₹6.2). 9M Revenue +8% to ₹551.35 Cr, PAT ₹134.89 Cr (-2% YoY, EPS ₹16.8). Exports are key (82% of Q3 revenue, led by Europe & Asia). Anesthetics remain the top therapeutic segment.

2. **Growth Drivers & Strategy:** Two new R&D centers (Lote & Ambernath) will drive 3-4 new API/formulation products annually.

Capacity boosted to 932 KLPD via Module E. New Ambernath formulation facility starts H2 FY26. 3. **Recent Developments:** Launched new Cardio Vascular & ADHD products; Liquid Anesthetics are commercial.

Secured a 10-year CMO deal with a European firm, targeting ₹60 Cr/year peak revenue from FY27. 4. **Key Financial Metrics (YoY):** Q3 Revenue +11%, PAT +6%. 9M Revenue +8%, PAT -2%. 5. **Outlook:** Management plans portfolio expansion (controlled drugs, anti-diabetics, anesthetics) leveraging R&D. Actively pushing into new global markets like North America, Japan, Australia, and New Zealand, supported by regulatory filings.